Previous 10 | Next 10 |
home / stock / nvmdf / nvmdf news
Chief Medical Officer will join expert panel on data and tech in psychedelic-assisted psychotherapy TORONTO, ON / ACCESSWIRE / October 4, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medic...
TORONTO, ON / ACCESSWIRE / September 30, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has opened its sixth integrative psychiatry clinic. The clinic is ...
TORONTO, ON / ACCESSWIRE / September 24, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that its common shares are now eligible for electronic clearing and settle...
Novamind to be featured in panel discussion on the disruptive potential of psychedelic medicine in mental healthcare TORONTO, ON / ACCESSWIRE / September 23, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized ...
TORONTO, ON / ACCESSWIRE / September 20, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has been included in the AdvisorShares Psychedelics ETF trading on...
NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the presentations from the September 16 th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live executive presentations ...
TORONTO, ON / ACCESSWIRE / September 14, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the Life Sciences Investor Forum, taking place virtua...
Cedar Clinical Research to Host Phase III Trial for Investigational Therapy for Schizophrenia TORONTO, ON / ACCESSWIRE / September 13, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine...
NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors, and industry professionals from around the world. This day-long virtual event will showcase live company presentations an...
TORONTO, ON / ACCESSWIRE / September 9, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that, effective today, its common shares have been approved for trading und...
News, Short Squeeze, Breakout and More Instantly...
The pressure is ramping up on the U.S. Drug Enforcement Administration (DEA) as more lawyers, clinicians, researchers, investors and business owners working in the psychedelics industry are demanding clear answers about how the DEA should be evolving on its drug scheduling and e...
TORONTO, ON / ACCESSWIRE / June 10, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, announced today that the Company has completed its previously announced acquisition by Numinus Welln...
Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. Numinus shareholders, at a separate meeting held today, have also approved the resolutions related t...